April 28, 2020Journal of Clinical OncologyOpen Access

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

View Full Paper

Ask AI

Bookmark

Abstract

I/T/DIN/GM-CSF has significant antitumor activity in patients with relapsed/refractory neuroblastoma. Study of chemoimmunotherapy in the frontline setting is indicated, as is further evaluation of predictive biomarkers.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mody et al. (2020) studied this question.

synapsesocial.com/papers/69da71b3ae64bec32b835e8c https://doi.org/10.1200/jco.20.00203

View Full Paper

Ask AI

Bookmark

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

Abstract

Discussion

Cite This Study

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

Abstract

Discussion

Cite This Study

Also Consider

Also Consider